Ingwer in der Phytotherapie: Fokus Onkologie

Zusammenfassung

Ingwer ist eine tropische Pflanze, welche im Wurzelstock 1,5–3% ätherisches Öl enthält. Ingwer fördert die Magenentleerung und den Magen-Darm-Transit und kann einen kurzfristigen Effekt bei der Behandlung und Prävention von Übelkeit und Erbrechen hervorrufen. Als in Pulverform anerkannte Arznei findet sie auch in der Onkologie Verwendung. Es konnte gezeigt werden, dass Ingwer bei Chemotherapie-induzierter Übelkeit/Erbrechen (CINV) behilflich sein könnte. Es gibt Hinweise, dass höhere Ingwerdosen weniger wirksam sind oder vorhandene Symptome verstärken können. Es liegen erste Ergebnisse vor, dass die Tagesdosis von 1 g nicht überschritten werden sollte. Weiterhin zeigte sich in einer Studie mit fraglicher Qualität, dass mit Ingwer behandelte Ovarialkarzinompatientinnen weniger Metastasen im Vergleich zur Kontrollgruppe aufwiesen. Studien, welche den Einfluss von Ingwer auf die Lebensqualität untersuchten, zeigen keine einheitlichen Ergebnisse. Weitere qualitative hochwertige Studien sind nötig, um die medizinische Wirksamkeit des Ingwers im onkologischen Kontext bestätigen und in der Praxis etablieren zu können.

Abstract

Ginger in Phytotherapy: Focus on Oncology

Ginger is a tropical plant, which consists of 1.5 to 3% essential oil in the rhizome. Ginger promotes gastric emptying and gastrointestinal transit and may produce a short-term effect in the treatment and prevention of nausea and vomiting. As a medicine approved in the form of powder, it is also used in oncology. It has been shown that ginger may be helpful in chemotherapy-induced nausea/vomiting (CINV). There is evidence that higher doses of ginger are less effective or may exacerbate existing symptoms. There are preliminary results that the daily dose of 1 g should not be exceeded. Furthermore, a study of questionable quality showed that ginger-treated ovarian cancer patients had fewer metastases compared to the control group. Studies investigating the impact of ginger on quality of life do not show consistent results. However, further high-quality studies are needed to confirm the medical efficacy of ginger in the context of oncology and to establish it in practice.

Schlüsselwörter

Ingwer - Phytotherapie - Naturheilkunde - Onkologie - klinische Studien

Key words

Ginger - phytotherapy - naturopathy - oncology - clinical trials, review

Publikationsverlauf

Artikel online veröffentlicht:
25. November 2021

• Literatur

• 1 European Medicines Agency, Committee on Herbal Medicinal Products (HMPC) Community herbal monograph on Zingiber officinale Roscoe, rhizoma. EMA/HMPC/749154/2010. 27 March. 2012
• 2 Shokri F, Gharebaghi PM, Esfahani A. et al Comparison of the complications of platinum-based adjuvant chemotherapy with and without ginger in a pilot study on ovarian cancer patients. International Journal of Women’s Health and Reproduction Sciences 2017; 5: 324-331 DOI: 10.15296/ijwhr.2017.55.
• 3 Bossi P, Cortinovis D, Fatigoni S. et al A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin. Ann Oncol 2017; 28: 2547-2551
• 4 European Medicines Agency, Committee on Herbal Medicinal Products (HMPC) Assessment report on Zingiber officinale Roscoe, rhizoma. EMA/HMPC/577856/2010. 27 March. 2012
• 5 Lee J, Oh H. Ginger as an antiemetic modality for chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. Oncology Nursing Forum 2013; 40: 163-170
• 6 Marx WM, Teleni L, McCarthy AL. et al Ginger (Zingiber officinale) and chemotherapy-induced nausea and vomiting: a systematic literature review. Nutrition Reviews 2013; 71: 245-254
• 7 Zick S, Ruffin M, Lee J. et al Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting. Support Care Cancer 2009; 17: 563-572
• 8 Marx W, McCarthy AL, Ried K. et al The effect of a standardized ginger extract on chemotherapy-induced nausea-related quality of life in patients undergoing moderately or highly emetogenic chemotherapy: A double blind, randomized, placebo controlled trial. Nutrients 2017; 9: 867
• 9 Thamlikitkul L, Srimuninnimit V, Akewanlop C. et al Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin-cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study. Support Care Cancer 2017; 25: 459-464
• 10 Konmun J, Danwilai K, Ngamphaiboon N. et al A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy. Med Oncol 2017; 34: 69
• 11 Arslan M, Ozdemir L. Oral intake of ginger for chemotherapy-induced nausea and vomiting among women with breast cancer. Clin J Oncol Nurs 2015; 19: E92-E97 DOI: 10.1188/15.CJON.E92-E97.
• 12 Sanaati F, Najafi S, Kashaninia Z, Sadeghi M. Effect of ginger and chamomile on nausea and vomiting caused by chemotherapy in Iranian women with breast cancer. Asian Pacific J Cancer Prev : APJCP 2016; 17: 4125-4129
• 13 Ansari M, Porouhan P, Mohammadianpanah M. et al Efficacy of ginger in control of chemotherapy induced nausea and vomiting in breast cancer patients receiving Doxorubicin-based chemotherapy. Asian Pacific J Cancer Prev : APJCP 2016; 17: 3877-3880
• 14 Raei M, Ghanbari A, Dadgari A. et al Effect of herbal therapy to intensity chemotherapy-induced nausea and vomiting in cancer patients. Iran Red Crescent Med J 2013; 15: 101-106 DOI: 10.5812/ircmj.4392.
• 15 Lua PL, Salihah N, Mazlan N. Effects of inhaled ginger aromatherapy on chemotherapy-induced nausea and vomiting and health-related quality of life in women with breast cancer. Complement Ther Med 2015; 23: 396-404 DOI: 10.1016/j.ctim.2015.03.009.
• 16 Salihah N, Mazlan N, Lua PL. The effectiveness of inhaled ginger essential oil in improving dietary intake in breast-cancer patients experiencing chemotherapy-induced nausea and vomiting. Focus on Alternative and Complementary Therapies 2016; 21: 8-16 DOI: 10.1111/fct.12236.
• 17 AWMF. S3-Leitlinie Komplementärmedizin in der Behandlung von onkologischen PatientInnen. Langversion 1.01. AWMF-Registernummer 032 - 055OL. Stand: 12.1.2021